KRAKacquisition Corp KRAQ

Financials SIC 6770 - Blank Checks NAICS Finance and Insurance › Funds, Trusts, and Other Financial Vehicles › Other Investment Pools and Funds › Other Financial Vehicles derived Nasdaq

We are a blank check company incorporated on July 28, 2025 as a Cayman Islands exempted company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share

purchase, reorganization or similar business combination with one or more businesses or entities (a "Business Combination").

While we may pursue an initial Business Combination in any business or industry or sector, we intend to concentrate our efforts on companies in the digital asset ecosystem. Our mission is to

accelerate the next phase of growth for the teams building the bridge between DeFi and TradFi. We expect to focus on companies developing the core infrastructure of the digital asset economy-payment networks, tokenization platforms, blockchain

Read the full description Show less

Last close 9.99 2026-10-23

Market cap $430.8M 2026-03-30 share count

52-week range 9.78 - 10.44

Valuation FY2025 figures against the last close

P/S—

P/E—

P/FCF—

EV/EBITDA—

Dividend yield—

Diluted EPS—

Annual financial statements

Balance sheet

Fiscal year	FY2025
Cash and equivalents	$44.1K
Total current assets	$44.1K
Total assets	$480.2K
Accounts payable	$11.4K
Total current liabilities	$557.5K
Total liabilities	$557.5K
Retained earnings	-$102.4K
Total equity	$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-012031.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)

Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity

Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks

No annual figures to plot for this company yet.

Recent filings and events

2026-03-30 Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
2026-03-19 Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
2026-02-04 Other event Item 8.01
2026-02-02 Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
2026-02-02 Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
2026-02-02 Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
2026-02-02 Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
2026-02-02 Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 6770

Ticker	Company	Market cap	P/E	Revenue growth
DMII	Drugs Made In America Acquisition II Corp.	$649.1M	—	—
IACO	Idea Acquisition Corp.	$437.9M	—	—
TACO	Berto Acquisition Corp.	$393.2M	36.1x	—
ALDF	Aldel Financial II Inc.	$328.0M	—	—
ATII	Archimedes Tech SPAC Partners II Co.	$290.3M	—	—
FGII	FG Imperii Acquisition Corp.	$290.3M	—	—
SOUL	Soulpower Acquisition Corp.	$269.3M	—	—
DMAA	Drugs Made In America Acquisition Corp.	$264.0M	—	—